Target intelligence / Profile preview

LARGE xylosyl- and glucuronyltransferase 2 (LARGE2)

Target
LARGE2
Molecular classification
Enzyme, Glycosyltransferase, Bifunctional glycosyltransferase
01

Overview

LARGE xylosyl- and glucuronyltransferase 2 (LARGE2) is a bifunctional enzyme with alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation and functional modification of alpha-dystroglycan and certain proteoglycans by glycosylation. It catalyzes the sequential addition of repeating disaccharide units (xylose and glucuronic acid) to form heteropolysaccharide chains, essential for extracellular matrix protein binding, particularly laminin. This modification is crucial for proper basement membrane stability and protein interactions. LARGE2 is mainly localized to the Golgi apparatus and exhibits a tissue distribution distinct from its paralog LARGE1, with high expression in kidney and placenta. Mutations or functional defects in LARGE2 are implicated in certain forms of muscular dystrophy associated with abnormal glycosylation of dystroglycan. Unlike LARGE1, LARGE2 can also modify specific proteoglycans beyond alpha-dystroglycan, suggesting a broader substrate specificity and specialized cellular roles in extracellular matrix organization and stability[1][2][4].

Other names
Xylosyl- and glucuronyltransferase LARGE2Alpha-1,3-xylosyltransferase LARGE2Beta-1,3-glucuronyltransferase LARGE2GYLTL1BPP5656FLJ35207Glycosyltransferase-like 1BGlycosyltransferase-like protein LARGE2Like-glycosyltransferase 2Ortholog of mouse glycosyltransferase-like 1B
02

Biological functions

Protein O-linked mannosylationDystroglycan bindingElongation of glucuronyl-xylose disaccharide repeatsPost-translational modification of alpha-dystroglycan (ECM receptor function)Proteoglycan biosynthetic modification
03

Disease associations

Muscular dystrophies (particularly Dystroglycanopathies, e.g., Muscular Dystrophy-Dystroglycanopathy, Type B, 6)Potential modifier of diseases associated with extracellular matrix defects
04

Safety considerations

No direct therapeutic compounds reported; potential concerns relate to off-target effects on extracellular matrix stability if targeted

Beyond the preview

Go deeper on LARGE xylosyl- and glucuronyltransferase 2 (LARGE2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LARGE xylosyl- and glucuronyltransferase 2 (LARGE2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call